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Abstract
Background: People living with HIV/AIDS (PLWH) have an excess risk for head 
and neck squamous cell carcinoma (HNSCC) compared to the general U.S. popula-
tion, but little is known about HIV-specific risk factors associated with the incidence 
and outcomes HNSCC. We aim to identify clinical and HIV-specific risk factors 
associated with oropharyngeal and non-oropharyngeal HNSCC incidence and out-
comes separately.
Methods: We constructed a retrospective cohort study of 45,052 PLWH aged 18 or 
above from the national Veteran Affairs (VA) Corporate Data from 1999 to 2015. We 
extracted demographic data and risk factor information, including history of alcohol 
abuse, smoking, CD4 count (cells/μl), and percent of follow-up time with undetect-
able HIV viral load as time-updated variables. We calculated the age-standardized 
incidence rates of oropharyngeal and non-oropharyngeal HNSCC and estimated ad-
justed hazard ratios (HR). We also examined overall survival using Kaplan–Meier 
curves and adjusted HR.
Results: The standardized incidence rate of oropharyngeal and non-oropharyngeal 
HNSCC in this veteran cohort of PLWH is 23.0 (95% confidence intervals (CIs): 
17.1-28.9) and 55.4 (95% CI: 46.5-64.3) per 100,000 person-years, respectively. 
Nadir CD4 count ≤200 was associated with an increased risk of non-oropharyn-
geal HNSCC (HR: 1.78; 95% CI: 1.31-2.30 vs >200). Five-year overall survival of 
OPSCC (37.0%) was significantly lower than non-oropharyngeal HNSCC (49.1%).
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1 |  INTRODUCTION
In the United States, approximately, 1.1 million people are 
living with HIV.1 The total number of newly diagnosed HIV 
cases has remained stable between 2012 and 2016, with 
about 38,000 new cases a year.1 Since the introduction of 
effective combination antiretroviral therapy (ART), the life 
expectancy of people living with HIV/AIDS (PLWH) has 
been approaching that of the non-HIV population.2 Thus, 
there is a concern of an increasing rate of non-AIDS-defin-
ing cancers, including head and neck cancers, whose inci-
dence sharply increases with aging in both HIV-infected and 
non-infected populations. PLWH have a higher incidence of 
both virus-related and tobacco/alcohol-related cancers due 
to a higher prevalence of HIV-induced inflammation, im-
munodeficiency, and tobacco use among PLWH compared 
with the non-HIV population.3,4 Indeed, as many as 20% of 
deaths among people living with HIV/AIDS is due to inva-
sive non-AIDS-defining cancers.
Squamous cell carcinoma of the head and neck region 
(HNSCC) includes the oral cavity, oropharynx, hypophar-
ynx, and larynx. Since HNSCC is strongly associated with 
tobacco use, the incidence for most of the sites has been de-
creasing.5,6 In stark contrast, the incidence of squamous cell 
carcinoma of the oropharynx (OPSCC) is rising at an epi-
demic rate due to its relationship with the human papilloma-
virus (HPV);6 OPSCC has now overtaken cervical cancer as 
the most common HPV-positive malignancy.7 Prior studies 
have shown that PLWH have an excess risk of HNSCC com-
pared to the non-HIV population, which could be due to a 
higher prevalence of tobacco and alcohol use. However, the 
elevated risk of lung cancer––another smoking-related can-
cer––is not entirely explained by smoking, suggesting HIV-
related immune suppression and chronic inflammation are 
also likely contributors.8 The drivers of increased HNSCC 
risk in PLWH patients are entirely unclear in the context of 
HPV-positive OPSCC. Since both HPV-negative and HPV-
positive head and neck cancers have high levels of immune 
infiltrate,9 suggesting the immune system plays an essential 
role in HNSCC development and survival.
Given the heterogeneity in the risk of HNSCC in people 
living with HIV and the importance of the immune system, 
we aimed to identify risk factors associated with oropharyn-
geal and non-oropharyngeal HNSCC in a large retrospective 
cohort study of PLWH identified in the U.S. national Veterans 
Health Administration (VHA) system. We also examined fac-
tors associated with survival among veterans living with HIV 
with HNSCC.
2 |  METHODS
2.1 | Study population and design
We performed a retrospective cohort study using individ-
ual-level patient data from the national VA Corporate Data 
Warehouse (CDW) and the VA Central Cancer Registry 
(CCR) from 1999 to 2015. Detailed information about cohort 
construction and inclusion has been previously described.10 
Briefly, the cohort of PLWH included patients aged 18 or 
above who fulfilled two out of the three following criteria: 
(1) patients with at least one positive HIV antibody test by 
Elisa or Western Blot; tested for HIV viral load (any +/-/
indeterminate); or tested for CD4+ count; (2) patients with 
at least one prescription in inpatient or outpatient phar-
macy records for HIV antiretroviral therapy (ART); and (3) 
any inpatient or outpatient encounter with an International 
Classification of Diseases, Ninth Revision (ICD-9) (042 or 
V08) or ICD-10 code (B20 & Z21) for HIV. We used the 
earliest date of the HIV diagnostic criteria as the index date 
of follow-up unless it was before 10/01/1999 (inception date 
of CDW data), in which case we assigned 10/01/1999 as the 
HIV patient's index date.
2.2 | Variable specification
2.2.1 | Outcomes
We are interested in two outcomes, first is HNSCC among 
the whole cohort and second survival among the HNSCC 
cohort (Figure 1). For the first incidence outcome (yellow 
box in Figure 1), we used a hierarchical approach to define 
the occurrence of OPSCC or non-oropharyngeal HNSCC in 
Conclusions: PLWH who receive care in the VA had higher age-adjusted HNSCC 
incidence rates than reported in the general population, suggesting that HIV and im-
munosuppression play a role. Additional studies should be conducted to study the 
interaction between HPV and HIV.
K E Y W O R D S
head and neck cancer, HIV, incidence, survival
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the cohort. First, we identified all head and neck squamous 
cancer cases in the VA CCR based on primary site of OPSCC 
and non-oropharyngeal HNSCC defined as oral cavity, hy-
popharynx, and larynx cancer. We then identified patients 
with any ICD-9 or ICD-10 code for HNSCC (Table S1). We 
examined the discordance of cancer diagnosis between the 
VA CCR and ICD-9/ICD-10 with a manual review of the 
electronic medical record (EMR) to determine their true can-
cer status. This hierarchical approach ensured a high validity 
of all the captured cancer cases. We then excluded all preva-
lent cancer cases that were diagnosed any time before the 
HIV index date through to 90 days after the index date.
For the second outcome of mortality (blue box in Figure 
1), all-cause mortality was identified from the VA Vital 
Status file, which combines information from Medicare, VA, 
Social Security, and VA compensation and pension benefits 
to determine the date of death with a sensitivity of 98.3% 
and specificity of 99.8% when compared with the National 
Death Index.11 During follow-up, only one female developed 
non-oropharyngeal HNSCC, and none developed OPSCC. 
Thus, we excluded female patients from this study.
2.2.2 | Covariates
We used a previously reported method to abstract and to clas-
sify covariates.12 Briefly, we extracted demographic data and 
risk factor information using ICD codes and pharmacy and 
laboratory data from the CDW, including age at index date, 
sex, race/ethnicity (White, Black, and other/unknown), his-
tory of alcohol abuse (yes, no), and smoking (ever or miss-
ing, never), and gastroesophageal reflux disease (GERD; 
ever, never). We defined baseline body mass index (BMI) by 
using the closest height and weight values in the 2 years be-
fore or after the index date. HIV-specific variables included 
were nadir CD4 count (cells/μL) and percent of follow-up 
time with undetectable HIV viral load, both as time-updated 
variables throughout the study period.
2.3 | Statistical analysis
2.3.1 | Incidence and risk factors for 
HNSCCs in veterans living with HIV
We compared baseline characteristics between patients with 
OPSCC, non-oropharyngeal HNSCC, and patients without an 
HNSCC diagnosis (i.e., controls) using a student's t-test for 
continuous variables and chi-square tests for categorical vari-
ables. Therefore, follow-up time at risk was calculated from 
90 days after the index date––the possible earliest start date 
of follow-up was 1/1/2000––to the development of HNSCC, 
death, or 12/31/2016, whichever was earlier. We calculated 
incidence rates age-standardized to the 2000 U.S. population 
for HNSCC in the PLWH per 100,000 person-years (PY) in 
oropharyngeal and non-oropharyngeal HNSCC separately. 
We then estimated adjusted hazard ratios (HR) and 95% con-
fidence intervals (CIs) for the risks of non-oropharyngeal 
F I G U R E  1  Schematic for the incidence (yellow box) and survival (blue box) study design
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T A B L E  1  Descriptive statistics of PLWH who received healthcare at VA from 1999 to 2015 by head and neck cancer diagnosis.
No cancer Oropharyngeal Non-oropharyngeal
p-value
n = 43,663 n = 119 n = 270
n (%) n (%) n (%)
Age at index date
<40 9889 (22.7) 14 (11.8) 28 (10.4) <0.001
40-59 28350 (64.9) 91 (76.5) 194 (71.9)
60 and above 5424 (12.4) 14 (11.8) 48 (17.8)
Race
Black 22847 (52.3) 68 (57.1) 131 (48.5) 0.041
Other/Unknown 4257 (9.8) 6 (5.0) 18 (6.7)
White 16559 (37.9) 45 (37.8) 121 (44.8)
Smoking
Ever or unknown smoker 35079 (80.3) 104 (87.4) 248 (91.9) <0.001
Lifelong non-smoker 8584 (19.7) 15 (12.6) 22 (8.1)
Alcohol abuse
No 24605 (56.4) 54 (45.4) 157 (58.1) 0.046
Yes 19058 (43.6) 65 (54.6) 113 (41.9)
Substance abuse
No 24957 (57.2) 55 (46.2) 161 (59.6) 0.039
Yes 18706 (42.8) 64 (53.8) 109 (40.4)
Baseline BMI
Missing 1543 (3.5) 3 (2.5) 7 (2.6) <0.001
<25 21063 (48.2) 77 (64.7) 157 (58.2)
25-29.9 14559 (33.3) 26 (21.8) 84 (31.1)
>30 6498 (14.9) 13 (10.9) 22 (8.1)
GERD (ever)
No 33277 (76.2) 78 (65.6) 166 (61.5) <0.001
Yes 10386 (23.8) 41 (34.5) 104 (38.5)
HCV (ever)
No 33882 (77.6) 80 (67.2) 198 (73.3) 0.006
Yes 9781 (22.4) 39 (32.8) 72 (26.7)
Nadir CD4 (at cancer/censor)
Missing 1409 (3.2) 2 (1.7) 10 (3.7) 0.061
≤200 21159 (48.5) 63 (52.9) 152 (56.3)
>200 21095 (48.3) 54 (45.4) 108 (40.0)
Viral load percentage of time 
undetectable (at cancer/censor)
Missing 1175 (2.7) 1 (0.8) 3 (1.1) 0.002
<40% 11081 (25.4) 34 (28.6) 98 (36.3)
40%-80% 11933 (27.3) 35 (29.4) 66 (24.4)
>80% 19474 (44.6) 49 (41.2) 103 (38.2)
Year first HIV
Before 1996 8582 (19.7) 41 (34.5) 80 (29.6) <0.001
1996-2000 10161 (23.3) 38 (31.9) 93 (34.4)
2001-2005 9240 (21.2) 20 (16.8) 63 (23.3)
2006-2016 15680 (35.9) 20 (16.8) 34 (12.6)
Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; HCV, Hepatitis C virus; PLWH, People living with HIV.
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HNSCC and OPSCC using Cox proportional hazards re-
gression models from index date plus 90 days to cancer or 
censor. We used forward selection to include covariates that 
changed estimates more than 10% or deemed clinically rel-
evant. We adjusted for age at index, race, smoking, baseline 
BMI, GERD, viral load percentage of time undetectable 
(time-dependent), nadir CD4 (time-dependent), and year first 
HIV diagnosis.
2.3.2 | Risk factors for mortality among 
People Living with HIV with HNSCC
We also examined survival using Kaplan–Meier curves for 
both oropharyngeal and non-oropharyngeal HNSCC as well 
as risk factors for mortality among PWLH with these cancers 
using Cox proportional hazards regression analysis the can-
cer date to death or censor. We examined the same potential 
confounder variables as examined in our Cox models for can-
cer incidence, as described above.
2.3.3 | HPV status exploratory analysis
To estimate the effect of HPV in OPSCC, we abstracted 
HPV status from medical records for all OPSCCs diag-
nosed after 2010 (HPV testing was not recommended 
2010).13 Cases were classified as HPV-positive if the 
case was positive for either p16 immunohistochemistry or 
HPV in situ hybridization and as HPV-negative if one test 
was negative and the other was unknown or untested. We 
compared univariate demographics and survival between 
HPV-positive, HPV-negative, and unknown HPV status at 
OPSCC diagnosis using statistics described above. We did 
not perform Cox regression given limited power due to re-
duced sample size.
Analyses were performed using SAS version SAS 
Enterprise Guide Version 7.15 (SAS Institute, Cary, NC). 
Statistical significance was determined at α=0.05, and 
P-values for statistical significance were two-sided.
3 |  RESULTS
3.1 | Descriptive statistics
We included data from 44,052 veterans living with HIV/
AIDS using VA healthcare. (Table 1). As expected, in our 
cohort, patients with OPSCC were younger than patients 
with non-oropharyngeal HNSCC (11.8% vs 17.8% older 
than 60 years at HIV index date, respectively) and controls 
(12.4% older than 60 years at HIV index date). OPSCC cases 
were more likely to be lifelong non-smokers compared with 
non-oropharyngeal HNSCC cases (12.6% vs 8.1% non-
smoker, respectively) and controls (19.7%). OPSCC cases 
were more likely to have a history of alcohol abuse (54.6% 
in OPSCC vs 41.9% non-oropharyngeal HNSCC) and sub-
stance abuse (53.8% in OPSCC vs 40.4% non-oropharyngeal 
HNSCC) compared with both noncancer subjects and non-
oropharyngeal HNSCC cases.
3.2 | Incidence of OPSCC and non-
oropharyngeal HNSCC in PLWH
Of the 44,052 PLWH in our nationwide VA cohort, there 
were 119 cases of incident OPSCC and 270 cases of non-oro-
pharyngeal HNSCC. The age-standardized rate of OPSCC 
was 23.0 (95% CI: 17.1-28.9) per 100,000 PY. The age-
standardized rate of non-oropharyngeal HNSCC was higher 
at 55.4 (95% CI: 46.5-64.3) per 100,000 PY.
In the adjusted Cox regression (Table 2), age greater 
than 60 years was associated with increased risk of both 
OPSCC (HR: 3.35; 95% CI: 1.56-7.18) and non-oropha-
ryngeal HNSCC (HR: 5.80; 95% CI: 3.58-9.39) compared 
with age <40  years in PLWH. Ever smoking was only 
associated with risk of developing non-oropharyngeal 
HNSCC but not OPSCC (HR: 2.38; 95% CI: 1.53-3.71 vs 
HR: 1.28; 95% CI: 0.73-2.23, respectively). Nadir CD4 
≤200 was associated with an increased risk of non-oropha-
ryngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30). GERD 
was also associated with the risk of non-oropharyngeal 
HNSCC (HR: 1.46; 95% CI: 1.14-1.87). Year of HIV di-
agnosis was significantly associated with decreased risk 
of both OPSCC (HR: 0.49; 95% CI: 0.28-0.85 for 2001-
2005 vs prior to 1999) and non-oropharyngeal HNSCC 
(HR: 0.56; 95% CI: 0.36-0.88 for 2006-2016 vs prior to 
1999).
3.3 | Survival for HNSCC in PLWH patients
Overall survival (OS) for OPSCC (5-year OS: 37.0%; Figure 
2) was significantly lower than that of non-oropharyngeal 
HNSCC (5-year OS: 49.1%; log-rank p-value=0.005). We 
further categorized non-oropharyngeal HNSCC into hy-
popharynx (n = 24), larynx (n = 120), nasopharynx (n = 11) 
and oral cavity (n = 115). Five-year OPSCC OS was lower 
than survival for both larynx (45.6%) and oral cavity cancer 
(65.4%; Figure S1A). These trends also continued when strat-
ified by smoking, where smokers with OPSCC had a worse 
survival than smokers with non-oropharyngeal HNSCC 
(Figure S1B). The 5-year OS in stage III–IV was lower than 
stage I-II in both OPSCC (I–II: 40.4%, III–IV: 30.9%, Figure 
S1C) and non-oropharyngeal HNSCC (I–II: 66.2%, III–IV: 
22.67%, Figure S1D).
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In multivariable Cox analysis for survival, ever smoking 
was significantly associated with increased risk of death, and 
BMI was associated with a decreased risk of death among both 
OPSCC and non-oropharyngeal HNSCC patients (Table 3). 
Although not significant, nadir CD4 count was also associated 
with OPSCC survival, where cases with nadir CD4 count less 
than or equal to 200 had 2.00 times the hazard of death (95% CI: 
0.94-4.27) compared to those with nadir CD4 greater than 200.
T A B L E  2  Mutually adjusted hazard ratios for the risk of oropharyngeal and non-oropharyngeal cancer in PLWH receiving healthcare at VA 
from 1999 to 2015.
Oropharyngeal Non-oropharyngeal
HR (95% CI) p-value HR (95% CI) p-value
Age at index
<40 1.00 1.00
40-59 2.17 (1.23, 3.84) 0.008 2.35 (1.57, 3.50) <0.001
60 and above 3.35 (1.56, 7.18) 0.002 5.80 (3.58, 9.39) <0.001
Race
White 1.000 1.00
Black 1.00 (0.68, 1.47) 0.993 0.77 (0.59, 0.99) 0.040
Other/Unknown 0.65 (0.28, 1.54) 0.329 0.75 (0.46, 1.24) 0.264
Smoking
Lifelong non-smoker 1.00 1.00
Ever or unknown smoker 1.28 (0.73, 2.23) 0.386 2.38 (1.53, 3.71) <0.001
Alcohol
No 1.00 1.00
Yes 1.81 (1.23, 2.66) 0.003 1.16 (0.90, 1.51) 0.253
Baseline BMI
<25 1.00 1.00
25-29.9 0.48 (0.31, 0.76) 0.001 0.79 (0.60, 1.03) 0.081
>30 0.63 (0.35, 1.14) 0.130 0.56 (0.35, 0.87) 0.010
Missing 0.50 (0.16, 1.62) 0.250 0.52 (0.24, 1.12) 0.092
GERD
No -- 1.00
Yes -- -- 1.46 (1.14, 1.87) 0.003
Viral load percentage of time undetectable 
(time-dependent)
<40% 1.00 1.00
40%-80% 1.19 (0.73, 1.95) 0.486 0.78 (0.56, 1.09) 0.144
>80% 1.29 (0.81, 2.07) 0.283 0.85 (0.63, 1.15) 0.288
Missing 1.50 (0.18, 12.28) 0.708 0.92 (0.27, 3.16) 0.895
Nadir CD4 (time-dependent)
>200 1.00 1.00
≤200 1.39 (0.95, 2.02) 0.088 1.78 (1.31, 2.30) <0.001
Missing 0.38 (0.51, 2.28) 0.112 1.14 (0.56, 2.30) 0.721
Year first HIV
Before 1996 1.00 1.00
1996-2000 0.82 (0.52, 1.27) 0.366 1.02 (0.76, 1.38) 0.880
2001-2005 0.49 (0.28, 0.85) 0.011 0.83 (0.59, 1.17) 0.282
2006-2016 0.69 (0.38, 1.26) 0.223 0.56 (0.36, 0.88) 0.011
Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; PLWH, People living with HIV.
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3.4 | HPV impact on OPSCC survival 
in PLWH
In our sensitivity analysis examining HPV in OPSCC, we 
found of the 62 cases diagnosed since 2010, 56.4% (n = 35) 
were tested for HPV. Of these, 88.6% (n = 31) were HPV-
positive and 11.4% (n = 4) were HPV-negative. Older indi-
viduals, smokers, and those whose cancer was first diagnosed 
before 2013 were less likely to be tested (Table S2). In a 
Kaplan–Meier curve (Figure 3), HPV-negative and unknown 
cases had worse OS (5-year OS: 18.3%) than HPV-positive 
cases (5-year OS: 59.4%).
4 |  DISCUSSION
In this large retrospective cohort study of veterans living with 
HIV using the nationwide VA healthcare system, we found 
that the age-standardized rate of non-oropharyngeal HNSCC 
is higher compared with age-standardized rates of OPSCC. 
The HIV-specific variable associated with non-oropharyn-
geal HNSCC was nadir CD4 count, which was associated 
with an increased risk of cancer. We are also the first study 
to demonstrate lower survival in OPSCC compared with la-
ryngeal and oral cavity cancer in both PLWH and veterans. 
This trend is consistent when stratified by stage. Upon further 
inspection, we found evidence that, although HPV-positive 
OPSCC has better survival than non-HPV OPSCC, survival 
is still lower in PLWH then the non-HIV population.
The incidence of HNSCC is higher in PWLH compared 
with the general SEER population,14,15 which is paralleled in 
our study where we see a higher incidence of both OPSCC 
and non-oropharyngeal HNSCC. PLWH tend to have 
more risk factors for cancer, such as risky sexual behavior, 
smoking, and immunosuppression.16 The age-standardized 
incidence of OPSCC and non-oropharyngeal HNSCC in our 
study is higher than previously reported in North American 
AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) consortium (40 per 100,000 person-years and 
10.7 per 100,000 person-years, respectively).3 The NA 
ACCORD consortium has pooled data from 17 prospective 
studies, including data from the VHA. However, our cohort 
was developed separately from the Veterans Aging Cohort 
(VACS) using a separate methodology. Additionally, male 
veterans who have a higher prevalence of cancer risk factors 
such as smoking and alcohol use thus represents a different 
target population from NA ACCORD.17
Overall, we see results similar to those observed in the 
NA ACCORD consortium. Age appears to one of the most 
significant risk factors for HNSCC among PLWH, which 
is relevant given the aging PLWH population. We found no 
association between HIV-related factors and OPSCC, sup-
porting previous research that immunosuppression is more 
relevant for non-HPV associated HNSCC than HPV-positive 
cancer.18,19 The increased but nonsignificant association of 
CD4 count may be due to the impact of CD4 early in HPV-
positive cancer by affecting HPV persistence. 20,21
On the contrary, for non-HPV-positive cancer, CD4 count 
would reflect reduced immune surveillance for malignant 
cells in the development of HNSCC.22 Alternatively, there 
is evidence that CD4 count decline could be due to undiag-
nosed cancer, rather than causing cancer. However, this has 
mainly been observed in lymphomas, and, in our study, the 
nadir CD4 count associated with cancer could be many years 
before the incident cancer diagnosis.
The relationship between GERD and non-oropharyngeal 
HNSCC is mixed with many earlier studies suggesting an 
association with hypopharynx or larynx cancer, but recent 
studies have not supported these findings.23-26 Our study is 
the first study of PLWH to examine GERD, in which we 
observed an association of GERD with non-oropharyngeal 
HNSCC. However, this association could be due to reverse 
causality, where the symptoms of laryngeal cancer mimic 
those of GERD. Thus, both are more likely diagnosed. Future 
studies may determine if this increased risk is simply due to 
detection bias.
This is the first large cohort study of HNSCC among 
PLWH that includes survival and stage. Survival in this co-
hort is lower than the SEER population for both OPSCC and 
non-oropharyngeal HNSCC. The lower survival compared 
to the non-veteran and non-HIV population could be due to 
the increased prevalence of smoking and medical conditions 
in the VA in addition to decreased immune response due to 
HIV. Low CD4 count is associated with increased risk of 
death in OPSCC, but not non-oropharyngeal HNSCC. HPV-
positive OPSCC tumors tend to have more immune infil-
trated and have higher levels of T cells. We also found the 
F I G U R E  2  Kaplan–Meier curve for survival after between 
oropharyngeal and non-oropharyngeal cancer
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survival of OPSCC to be much lower than the survival of 
non-oropharyngeal HNSCC, even given the lower prevalence 
of suggesting there is an interaction between HIV and HPV 
in OPSCC. Coupled with increased risk among PLWH, im-
munity may play a more crucial role in HPV-positive cancers 
than in non-HPV-positive HNSCCs.
In a subset analysis, we found that among the cases tested 
for HPV, the majority are HPV-positive, which is similar to 
previous studies of HPV status in OPSCC in the VA.27 We also 
found that although HPV-positive OPSCC cases have better 
survival than HPV-negative OPSCC, they still have lower 
survival than the non-HIV population. Two-year survival for 
HPV-positive OPSCC for all stages has been reported to be as 
high at 90% in the non-HIV non-Veteran population.28,29 This 
difference in survival signifies that host immune likely plays 
an essential role in the increased survival of HPV-positive 
OPSCC. Smoking is also a likely driver of poor outcomes, 
particularly in the Veteran population with high rates of 
tobacco use. Smoking worsens prognosis in HPV-positive 
OPSCC, increasing the risk of death by 1% for every one 
pack-year of smoking.30-32 However, to date, few studies have 
considered the interaction between HIV and HPV in OPSCC, 
and one previous study of OPSCC among PWLH found no 
difference in survival by HPV status,33 This discordance jus-
tifies additional examination of the interaction between HPV 
and HIV in OPSCC specifically.
Given both the increased risk of HNSCC and higher rates 
of death from HNSCC among PLWH, there is a strong case 
for dysfunctional immunity as a driver of poor HNSCC out-
comes in this population. Both HPV- and tobacco-associ-
ated HNSCCs have an immunosuppressive tumor immune 
microenvironment.34,35 Specifically, HPV-positive OPSCC 
inherently represents a failure of host immunity, allowing 
HPV infection, persistence, and progression to carcinoma go 
unchecked. In the non-HIV population, improved survival 
may be in part due to enhanced immune response induced by 






N (%) HR (95% CI) p-value N (%) HR (95% CI) p-value
Age at index date
<40 14 (11.8) 1.00 28 (10.4) 1.00
40-59 91 (76.5) 1.04 (0.40, 2.69) 0.939 194 (71.9) 5.91 (1.85, 18.87) 0.003
60 and above 14 (1.8) 2.41 (0.75, 7.80) 0.141 48 (17.8) 9.04 (2.68, 30.45) <0.001
Smoking
Non-smoker 104 (87.4) 1.00 248 (91.9) 1.00
Ever or unknown smoker 15 (12.6) 2.96 (1.25, 6.99) 0.013 22 (8.1) 3.31 (1.35, 8.12) 0.009
Baseline BMI
<25 77 (66.4) 1.00 157 (59.5) 1.00
25-29.9 26 (22.4) 0.80 (0.43, 1.49) 0.489 85 (32.2) 0.51 (0.34, 0.76) 0.001
>30 13 (11.2) 0.26 (0.09, 0.74) 0.012 22 (8.3) 0.86 (0.41, 1.81) 0.690
Viral load percentage 
of time undetectable 
(time-dependent*)
<40% 28 (23.7) 1.00 61 (22.8) 1.00
40%-80% 39 (33.1) 1.31 (0.73, 2.34) 0.369 98 (36.7) 0.89 (0.58, 1.36) 0.588
>80% 51 (43.2) 0.71 (0.38, 1.32) 0.284 108 (40.4) 0.78 (0.51, 1.19) 0.244
Nadir CD4 (time-dependent*)
>200 106 (89.1) 1.00 195 (73.0) 1.00
≤200 13 (10.9) 2.00 (0.94, 4.27) 0.072 72 (27.0) 1.11 (0.75, 1.64) 0.597
Stage
I-II 22 (18.5) 1.00 119 (44.1) 1.00
III-IV 86 (72.3) 1.52 (0.86, 2.71) 0.153 94 (34.8) 2.63 (1.79, 3.88) <0.001
Unknown 11 (9.2) 0.70 (0.22, 2.26) 0.549 57 (21.1) 1.55 (0.97, 2.48) 0.069
Abbreviation: BMI, body mass index.
*N (%) is at cancer/censor 
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radiation therapy.9,36 ART-associated immune reconstitution 
fails to completely restore immune populations required for 
successful control of cancer after radiation therapy.
Our study has several limitations. First, it was a histori-
cal cohort and may be subject to unmeasured confounders 
such as sexual behavior and misclassification of covari-
ates. However, we attempted to adjust for this through 
ICD-9 codes identifying individuals with a history of both 
alcohol and drug use. Although we were able to abstract 
HPV data on some of the OPSCC cases, we lacked in-
formation about the tumor HPV status of for most of the 
OPSCC cases, since only about half the cases after 2010 
were tested for HPV. Finally, this study was limited to 
male veterans. Veterans are a select group that has lower 
socioeconomic status, more medical conditions, which 
would limit the generalizability to the other populations 
of PWLH.37
Our study has multiple notable strengths. The VHA is 
the most extensive integrated healthcare system and provider 
of comprehensive HIV care in the United States. By taking 
advantage of the comprehensive fully automated nationwide 
VA clinical, laboratory, and administrative databases (CDW 
and CCR) along with manual electronic medical records 
abstractions, we constructed a large cohort of PLWH with 
extensive follow-up and individual-level data. Additionally, 
this is the largest study published to date evaluating HNSCC 
survival among PLWH.
In summary, HNSCC is more common among PLWH 
than in the general U.S. population. Certain HIV-specific 
variables such as CD4 count are associated with increased 
risk suggesting that HIV, and thus, the host immune system, 
in addition to increased prevalence of head and neck risk fac-
tors such as smoking and HPV, increases the risk of HNSCC. 
As the prevalence of both HIV rises in the United States due 
to better survival and the incidence of HPV-positive OPSCC 
increases, the interaction between the HPV and HIV be-
comes increasingly relevant, especially since HPV-positive 
OPSCCs among PLWH in our cohort do not have the gener-
ally favorable survival seen in the non-HIV population. This 
growing concern needs a dedicated effort and resources as 
well as additional studies to study the interaction between 
HPV, tobacco, and HIV in OPSCC.
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